Aspartate-β-hydroxylase as a promising prognostic and therapeutic biomarker for HBV-positive hepatocellular carcinoma
Jingtao Li,Zongwen Wang,Xiaohang Ren,Qiankun Zhu,Yao Zhang,Shuoheng Ma,Wenyu Liu,Shicong Zeng,Bo Zhai
DOI: https://doi.org/10.21203/rs.3.rs-2984696/v1
2023-01-01
Abstract:Abstract BACKGROUND: Hepatitis B virus (HBV) is a key factor in the development of hepatocellular carcinoma (HCC). However, effective treatments to improve prognosis are still lacking. Aspartate plays a critical role not only in tumor cell proliferation, invasion, and migration, but also in the tumor immune microenvironment. A deeper understanding of the cellular and molecular mechanisms of HBV-positive HCC in terms of the role of aspartate-related genes may contribute to the development of targeted methods for prevention and treatment. Methods: Transcriptomic data and clinical information on HCC samples from TCGA, GEO, and ICGC databases were obtained for assessing prognosis and variable genetic information. We collected a total of 79 clinical samples, including 66 cases of HBV-positive HCC and 13 cases of HBV-negative HCC, along with corresponding clinical information. Subsequently, ASPH immunohistochemical staining was performed on the samples, enabling the analysis of ASPH expression and its prognostic implications for the patients. In vitro, we demonstrated the effect of ASPH expression on malignant progression of HCC by examining the proliferation, invasion, and migration of various hepatocellular carcinoma cell lines. Transcriptomic data were analyzed to confirm potential mechanisms and validated by western blotting and immunohistochemical staining. Results: Clinical prognostic models can influence the prognosis of HBV-positive HCC patients. ASPH acts as an independent factor affecting prognosis in HBV-positive HCC patients, but not in HBV-negative cases. In vitro, knockout of ASPH inhibited the proliferation, invasion and migration of tumor cells, while its overexpression exhibited a promoting effect. Mechanistically, ASPH demonstrates a close correlation with disulfidoptosis and tumor immunity. Notably, we have identified ASPH can regulate the expression of SLC7A11, NCKAP1, and mTOR. Moreover, the expression of ASPH can be associated with the infiltration of immune cells in tumor tissues. Conclusions: Our research established the optimal model to predict the prognosis of HBV-positive HCC patients. Furthermore, we demonstrated that ASPH plays a critical role in the prognosis, immunological microenvironment, and drug sensitivity of HBV-positive HCC patients. Disulfidoptosis and tumor immunity are possible mechanisms of ASPH function.